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Background: Considering previous result in Non-Small Cell Lung Cancer (NSCLC), we investigated in human cancer
cells the role of PARP3 in the regulation of telomerase activity.
Methods: We selected A549 (lung adenocarcinoma cell line) and Saos-2 (osteosarcoma cell line), with high and low
telomerase activity levels, respectively. The first one was transfected using a plasmid construction containing a PARP3
sequence, whereas the Saos-2 cells were submitted to shRNA transfection to get PARP3 depletion. PARP3 expression on
both cell systems was evaluated by real-time quantitative PCR and PARP3 protein levels, by Western-blot. Telomerase
activity was determined by TRAP assay.
Results: In A549 cells, after PARP3 transient transfection, data obtained indicated that twenty-four hours after transfection,
up to 100-fold increased gene expression levels were found in the transfected cells with pcDNA/GW-53/PARP3 in
comparison to transfected cells with the empty vector. Moreover, 48 hours post-transfection, telomerase activity
decreased around 33%, and around 27%, 96 hours post-transfection. Telomerase activity average ratio was 0.67 ±
0.05, and 0.73 ± 0.06, respectively, with significant differences. In Saos-2 cells, after shRNA-mediated PARP3 silencing, a
2.3-fold increase in telomerase activity was detected in relation to the control.
Conclusion: Our data indicated that, at least in some cancer cells, repression of PARP3 could be responsible for an
increased telomerase activity, this fact contributing to telomere maintenance and, therefore, avoiding genome
instability.
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Poly (ADP-ribose) polymerase 3 (PARP3) is a novel
member of the PARP family, a group of enzymes that
synthesize poly (ADP-ribose) on themselves or other
acceptor proteins. Recent findings suggest that PARP3
catalyses a post-translational modification of proteins
involved in biological processes, such as transcriptional
regulation, energy metabolism and cell death [1,2].
Other members from this protein group, PARP1 and
PARP2, have been described as active players of the* Correspondence: insepi@ucm.es
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article, unless otherwise stated.base excision repair process, thus defining its key role
in genome surveillance and protection [3].
Human PARP3 has been found to associate with Poly-
comb group proteins involved in transcriptional silencing
and with DNA repair networks, including base excision
repair/single-strand break repair (BER/SSBR) and nonho-
mologous end-joining (NHEJ), suggesting an active role
for PARP3 in the maintenance of genomic integrity [3].
PARP3 has been described as a critical player in the
stabilization of the mitotic spindle and in telomere in-
tegrity notably by associating and regulating the mitotic
components NuMA and Tankyrase 1. Both functions
open stimulating prospects for specifically targeting
PARP3 in cancer therapy [4]. These findings reveal
PARP3 as a positive regulator of the mitotic network
containing Tankyrase 1 and NuMA with fundamentaled Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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during mitosis. Additional studies are required to deter-
mine the specific inducers of PARP3 activity [5].
As it is well known, telomere function and DNA damage
response pathways are frequently inactivated in cancer.
Previous results from our group indicated that telomere
attrition was significantly associated with poor clinical
evolution of patients affected by Non-Small Cell Lung
Cancer (NSCLC), independently of tumour TNM stage.
In addition, a number of genes related to DNA-repair
were found significantly down-regulated in non-small
cell lung tumours showing positive telomerase activity,
being PARP3 one of these molecules [6]. These data
may be considered of interest in NSCLC, since PARP3
maps in chromosome 3p (3p21.31-p21.1), and 3p de-
letions constitute one of the most frequent events
described in relation to NSCLC. Moreover, previous
results from our group and others [7] suggested the
existence on 3p of one or several genes implicated on
telomerase negative regulation.
Thus, considering PARP3 implication in the mainten-
ance of genomic integrity, as well as previous results
suggesting a negative correlation between PARP3 ex-
pression and telomerase activity in non-small cell lung
tumours, our main aim in this work consists of investi-
gating in human cancer cell lines the possible role of
PARP3 on the regulation of telomerase activity, which
may be of relevance in the pathogenesis of NSCLC.
Materials and methods
In order to investigate the possible role of PARP3 on tel-
omerase regulation, we selected two human cell lines
showing significantly different levels of telomerase activ-
ity. Thus, we performed “in vitro” assays on the human
lung carcinoma cell line A549, with high telomerase ac-
tivity, and Saos-2 human osteosarcoma cells, underlying
low telomerase activity levels. The first one of the two
cell systems was transfected using a plasmid construc-
tion containing a PARP3 sequence, whereas the Saos-2
cells were submitted to shRNA transfection in order to
get PARP3 depletion.
Cell cultures
The human lung carcinoma cell line A549 (kind gift from
Dr. Paloma Navarro, Spanish National Cancer Research
Centre, CNIO) was grown in Ham’s F-12 K (Kaighn’s)
medium (Life Technologies, Carlsbad, California), supple-
mented with 10% fetal bovine serum (FBS) (Life Techno-
logies), antibiotic-antimycotic 1X (Life Technologies) and
Plasmocin™ 5 μg/ml (InvivoGen, San Diego, California).
Saos-2 human osteosarcoma cells were purchased from
the American Type Culture Collection (ATCC, Manassas,
VA, USA), cultured in Dulbecco’s modified Eagle’s
medium (DMEM, Life Technologies) and supplementedas Ham’s F-12 K (Kaighn’s) medium. Cell cultures were
maintained at 37°C under 5% CO2.
Plasmid transfection
A549 cells were transiently transfected with 4 μg of plas-
mid DNA/dish (60x15 mm) using Lipofectamine™ 2000
Reagent (Life Technologies), according to the manufac-
turer’s standard protocol. Plasmids used were pcDNA/
GW-53/PARP3 (containing the PARP3 sequence of short
isoform) and pcDNA-DEST53 empty vector, as control.
Both were developed in our laboratory using the Gateway®
(Life Technologies) Technology.
shRNA transfection
We used the shRNA technology (SureSilencing™ shRNA
Plasmids, SABiosciences, Valencia, California) in Saos-2
cells to generate stable transfectants depleted in PARP3.
Four shRNAs targeting the gene of interest were supplied.
As transfection system we employed magnet assisted
Transfection (MATra)® (BioTAGnology, St. Louis, MO) in
combination with cationic liposomes, and transfected cells
with a non-functional shRNA as control. Transfected cells
were selected by adding 1 μg/ml of puromycin for 3 weeks.
RNA extraction, reverse transcription and real-time
quantitative PCR (qRT-PCR)
Total RNA was extracted from A549 and Saos-2 human
cells using TRIzol™ Reagent (Life Technologies) accord-
ing to the manufacturer’s instructions. Reverse tran-
scription reactions were performed with 2 μg of total
RNA using the High Capacity cDNA reverse transcrip-
tion kit (Applied Biosystems, USA) following the manu-
facturer’s instructions. Overexpression and silence of
PARP3 were determined by qRT-PCR using the Taqman
probe Hs00193946_m1 (FAM™ dye-labeled TaqMan®
MGB probes, Applied Biosystems).
In A549 cells, we determined the expression level of
PARP3 in transfected cells with pcDNA/GW-53/PARP3
and pcDNA-DEST53 empty control vector, 24, 48 and
96 hours post-transfection. For quantification of gene
expression, the target gene values were normalized to
the expression of the endogenous reference PPIA
(Cyclophilin A expression, Hs99999904_m1). In Saos-2
cells, PARP3 expression level was evaluated by qRT-PCR
in silenced with shRNA cells and in the transfected with
the control plasmid, determining the genetic silencing
ratio. The target gene values were normalized to the ex-
pression of the endogenous reference GAPDH (Glycerade-
hyde-3-phosphate dehydrogenase, Hs99999905_m1). The
comparative threshold cycle (Ct) method was used to
calculate the relative expression. For quantification of gene
expression, the target gene value was normalized to
the expression of the endogenous reference. The amount
of target, normalized to the endogenous reference and
Fernández-Marcelo et al. Journal of Experimental & Clinical Cancer Research 2014, 33:19 Page 3 of 8
http://www.jeccr.com/content/33/1/19relative to the control is given by 2-ΔΔCt (Relative Quantifi-
cation, RQ). (ΔCt = Ct target gene – Ct endogenous reference;
ΔΔCt =ΔCt transfected – ΔCt control).
Western-blot analysis
Fifteen micrograms of total protein were loaded on 8%
SDS-PAGE and transferred to a nitrocellulose mem-
brane (Whatman GmbH, Dassel, Germany). Blots were
blocked with PBS containing 0.1% Tween-20 (PBST)
and 5% powdered skim milk (PBSTM) 1 hour at room
temperature and incubated overnight 4°C with rabbit
polyclonal PARP3 antibody diluted 1:1000 in PBSTM
(Alexis Biochemicals, San Diego, California; kind gift from
Dr. Michèle Rouleau, Guy Poirier Laboratory, Québec,
Canada). After washing with PBST, blots were incubated
for 1 hour at room temperature with the secondary
anti-rabbit antibody (Sigma-Aldrich, St Louis, Missouri)
diluted at 1:1000 in PBSTM. After washing with PBST,
blots were developed using Pierce ECL 2 Western Blotting
Substrate (Thermo Scientific, Waltham, Massachussets).
β-actin was used as loading control. Cells that expressed
at higher levels the short isoform (SK-N-SH), as verified
by siRNA knock down, were used as reference (kind gift
from Dr. Michèle Rouleau, Guy Poirier Laboratory,
Québec, Canada) [8]. Intensity of individual bands was
quantified using Image J densitometry software, and
expressed relative to β-actin signal, as a measure of pro-
tein relative abundance in the different conditions.
Telomerase activity assay
Telomerase activity was determined in A549 transfected
cells (24, 48 and 96 hours post-transfection) and in Saos-2
cells with the highest ratio of genetic silencing, by Te-
loTAGGG Telomerase PCR ELISA (Roche Applied Sci-
ence, Penzberg, Germany) as previously published [9].
This method is an extension of the original Telomeric
Repeat Amplification Protocol (TRAP) [10]. Briefly, in a
first step, a volume of cell extract containing 10 μg of
total proteins was incubated with a biotin-labelled syn-
thetic telomerase-specific primer, and under established
conditions, telomerase present in cellular extracts adds
telomeric repeats (TTAGGG) to the 3′ end of the pri-
mer. In a second step, these elongation products were
amplified by PCR using specific primers. An aliquot of
the PCR products was denatured, hybridized to a digox-
igenin labelled, telomeric repeat-specific probe, and
bound to a streptavidin-coated microtiter plate. The
immobilized PCR products were then detected with
an antibody against digoxigenin that was conjugated to
peroxidase. Finally, the probe was visualized by virtue of
peroxidase-metabolizing TMB to form a coloured reaction
product and semiquantified photometrically (450 nm).
Thus, considering that the cut-off for telomeric repeat
amplification protocol-ELISA negativity corresponds tooptical density (OD)450 nm less than 0.2, all samples with
OD450nm >0.2 were considered as telomerase positive.
As positive control we used an extract of the telomerase-
positive embryonic kidney cell line 293, and negative con-
trols were prepared in each case by treating cell extracts
with DNase-free RNase. The sensitivity of the procedure
was sufficient to detect telomerase activity in an extract
that contained 10 cell of the telomerase-positive cell line
used as control. To avoid the effect of Taq polymerase
inhibitors present in the cell extracts, we estimated the
activity of telomerase by serial dilutions of each extract as
described previously [11].
Telomerase activity ratios were determined as follow:
[Absorbance (450nm) of the protein extracts from A549
cells transfected with pcDNA/GW-53/PARP3 vector]/
[Absorbance (450nm) of the protein extracts from A549
cells transfected with pcDNA-DEST53]; [Absorbance
(450nm) of the protein extracts from Saos-2 cells with
the highest decrease of PARP3, silenced with shRNA]/
[Absorbance (450nm) of the protein extracts from Saos-2
cells, transfected with a non-functional shRNA].
PCR products were separated by polyacrylamide gel elec-
trophoresis (PAGE), blotted onto a positively charged mem-
brane, and chemioluminiscent detection was performed.
Statistical analysis
Statistical analyses were developed using IBM SPSS Sta-
tistics 19 software. The paired samples T test was used
for comparing the means of two variables, after testing
normality condition by one sample Kolmogorov Smirnov
test (K-S test).
Results
Transient over-expression of PARP3 and decrease in
telomerase activity in A549 cell line
Initially, we evaluated mRNA PARP3 levels by qRT-PCR
in A549 cell line to provide reference values. Moreover,
we checked telomerase activity in this cell line. Results
revealed that the enzyme was highly active in A549 cells.
Our data indicated that A549 cell line showed a Delta
Ct = 8.88, according to results from qRT PCR for PARP3
analysis. In order to validate these data, we evaluated
telomerase activity and PARP3 expression in a cell line
from similar origin, such as H522 (stage 2, adenocarcin-
oma, non-small cell lung cancer). In this case, high levels
of telomerase activity correlated with similar values to
those of A549 cell line for PARP3 expression (Delta Ct =
9.14). Thus, it was considered that the best approach was
to overexpress PARP3 in this cell line in order to check if
telomerase activity decreased.
After PARP3 transient transfection, qRT-PCR was per-
formed to measure the relative expression level of PARP3.
Data obtained indicated that twenty-four hours after
transfection, up to 100-fold increased gene expression
Figure 2 Telomerase activity in A549 cells after transient
transfection. Time course of telomerase activity ratios [Absorbance
(450 nm) of the protein extracts from A549 cells transfected with
pcDNA/GW-53/PARP3 vector]/[Absorbance (450 nm) of the protein
extracts from A549 cells transfected with pcDNA-DEST53], after
transient transfection. (Data are the average of four experiments,
media ± standard error).
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GW-53/PARP3 in comparison with the transfected cells
with the empty vector. Forty-eight hours after transfec-
tion, > 60-fold increased, and 96 hours after, PARP3
mRNA levels in the transfected cells with pcDNA/GW-
53/PARP3 were similar to PARP3 mRNA levels in the
transfected cells with the empty vector (Figure 1).
In relation to telomerase activity, 24 hours post-
transfection no differences were found between trans-
fected cells with pcDNA/GW-53/PARP3 and transfected
cells with the empty vector. Telomerase activity average
ratio was 1.08 ± 0.05 (media ± standard error). Forty-eight
hours post-transfection, telomerase activity decreased
around 33% in the transfected cells with pcDNA/GW-53/
PARP3 in comparison with the transfected cells with
the empty vector. Telomerase activity average ratio was
0.67 ± 0.05. Finally, at 96 hours after transfection, tel-
omerase activity diminished around 27% in the trans-
fected cells with pcDNA/GW-53/PARP3 with regard to
transfected cells with the empty vector. Telomerase
activity average ratio was 0.73 ± 0.06. Significant dif-
ferences between telomerase activity average ratio at
24 hours after transfection vs. 48 hours, and 24 hours
vs. 96 hours were found (P-values: 0.026 and 0.011,
respectively; Paired Samples T Test) (Figure 2). Repre-
sentative examples of telomerase activity on PAGE are
shown in Figure 3. Furthermore, Western-blot analysis
revealed that PARP3 protein levels increased at 48 and
96 hours after transfection. As it can be observed in
Figure 4, PARP3 increased 3.19 and 1.6-fold at 48 and
96 hours, respectively, in the transfected cells with
pcDNA/GW-53/PARP3 in comparison with the trans-
fected cells with pcDNA-DEST53 empty vector.Figure 1 Time course of PARP3 expression levels by qRT-PCR
after transient transfection, in A549 cells. Bars are the average of
three experiments, media ± standard error.Decrease of PARP3 and increase in telomerase activity in
Saos-2 cell line
In the cell line Saos-2 we initially developed an approach
similar to that described for the A549 line. Thus, in
order to characterize this cell line we evaluated PARP3
mRNA levels by qRT-PCR, and analyzed telomerase
activity. Results revealed low levels of enzyme activity.
Following, we performed experiments aimed at silencing
PARP3 in this cell line, then checking whether this silen-
cing led to an increase in telomerase activity in cells.
shRNA-mediated gene silencing allowed us to select the
clone of Saos-2 cells with the highest reduction of PARP3,
whose mRNA levels decreased by 60% with respect to the
control, as qRT-PCR assays showed (Figure 5A). Western-
blot was used to validate the results of quantitative real-
time PCR: PARP3 protein levels decreased more than
2-fold in Saos-2 cells with the highest decrease of PARP3,
compared to the control (Figure 5B).
The clone of Saos-2 cells with the highest decrease of
PARP3 expression showed a significant (P-value: 0.003,
Paired Samples T Test) increase in telomerase activity
(2.3-fold increase), compared to the control, which was
transfected with a non-functional shRNA (Figure 6A). As
before, telomerase activity results on PAGE are shown
(Figure 6B).
Discussion
The considerable progress in the science of PARPs in
the last years has introduced these proteins function as a
key mechanism regulating in a wide variety of cellular
processes including, among others, telomere homeosta-
sis. Recently, De Vos et al. have suggested that one of
Figure 3 Representative examples of telomerase activity on Polyacrylamide Gel Electrophoresis (PAGE) in A549 transfectants are
shown. (A) 24 and 48 hours after trasfection. (B) 96 hours after transfection.
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field is to further dissect the biological activities of the
emerging DNA-dependent PARPs (i.e. PARP3, Tankyr-
ase), and to exploit their known structural features for
the rational design of selective and potent PARP inhi-
bitors [12]. Recent results identified PARP3, the third
member of the PARP family, as a newcomer in DBS
repair [13,14]. PARP3 has been found to regulate mitotic
progression by stimulating the Tankyrase 1 catalyzed auto
(ADP-ribosyl) ation and hetero (ADP-ribosyl) ation of the
mitotic factor NuMA (nuclear mitotic apparatus protein
1) [14]. Tankyrase 1 is denoted as a telomere associated
PARP involved in the release of the telomeric proteinTRF1, via its PARsylation to control access and elongation
of telomeres by telomerase [15].
In this work, we observed that PARP3 depletion in
lung cancer cells resulted in increased telomerase activ-
ity. Moreover, in cancer cells with low telomerase activ-
ity, PARP3 showed high expression levels. These results
seem to indicate an inverse correlation between telomer-
ase activity and PARP3 expression in cancer cells. Ac-
cording to our data, in A549 cells the highest mRNA
PARP3 levels were detected 24 h after transfection.
However, the highest levels for depletion in telomerase
activity ratio were achieved 48 h after transfection,
obtaining similar values to these 96 h after transfection.
Figure 4 Western-blot assay for testing PARP3 protein levels in A549 cells after transient transfection. Bars are the average of three
experiments, media ± standard error.
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highest levels in PARP3 protein. Therefore, our results
seem to indicate that PARP3 could act as a negative
regulator of telomerase activity. Several studies have
provided insights into the biochemical and structural
properties of PARP3 [13,16]. However, its physiologicalFigure 5 PARP3 mRNA expression and protein levels in Saos-2 cells a
after shRNA transfection (data are the average of triplicate experiments, me
levels in Saos-2 cell line (bars are the average of three experiments, mediafunctions remain unknown. Recently, it has been pro-
vided evidence for two distinct roles of PARP3 in gen-
ome maintenance and mitotic progression [4]. Thus, a
role of PARP3 in cellular response to DNA damage, in re-
sponse to DSBs, has been emphasized. Also, it has been
suggested a functional synergy of PARP1 and PARP3 infter transfection. (A) Analysis of PARP3 expression levels by qRT-PCR,
dia ± standard error). (B) Western-blot assay for testing PARP3 protein
± standard error).
Figure 6 Telomerase activity in Saos-2 cells after transfection. (A) Telomerase activity ratios [Absorbance (450 nm) of the protein extracts
from Saos-2 cells with PARP3 down-regulated]/[Absorbance (450 nm) of the protein extracts from Saos-2 cells control] (data are the average of
three experiments, media ± standard error). (B) Telomerase activity on Polyacrylamide gel Electrophoresis (PAGE).
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covered essential functions of PARP3 in orchestrating the
progression through mitosis by at least two mechanisms,
including promotion of telomere integrity [4]. We now
propose a potential negative correlation between PARP3
levels of expression and telomerase activity that also
could result in telomere dysfunction. In fact, we had ob-
served in NSCLC a significant PARP3 down-regulation
in telomerase positive tumors in relation to telomerase
negative cases. Also, in NSCLC we had demonstrated a
poor clinical evolution of patients affected by tumors in
which telomere attrition was detected [6].
Our results suggest that the role of PARP3 in main-
taining telomere integrity could be performed though
regulation of telomerase activity. Therefore, depletion of
PARP3 expression could result in a defective telomerase
activity. According to this hypothesis, previous experimen-
tal data had demonstrated that several normal human
chromosomes, including chromosomes 3, 4, 6, 7, 10, and
17, repress telomerase activity in some cancer cells [17].
Thus, Horikawa et al. identified the E-box downstream
of the transcription initiation site that was responsible for
telomerase repressive mechanisms restored by normal
chromosome 3 targets. This E-box-mediated repression is
inactivated in various types of normal human cells andinactivated in some, but not all, hTERT-positive cancer
cells. These findings provide evidence for an endogenous
mechanism of hTERT transcriptional repression, which
becomes inactivated during carcinogenesis [18].
In Non-Small Cell Lung tumors, we had previously
described a negative correlation between PARP3 expres-
sion and telomerase activity [6]. In fact, we detected that
PARP3 showed a significant down-regulation in associ-
ation with telomerase activity. PARP3 maps in chromo-
some 3p (3p21.31-p21.1), and chromosome 3p deletions
constitute one of the most frequent events described
in relation to NSCLC pathogenesis. Additional previous
data from our group and others [7] also suggested the
existence on 3p of one or several genes implicated on
telomerase negative regulation.
Therefore, data reported in this work contribute to dem-
onstrate that PARP3 could act as a negative repressor of
telomerase activity with relevance in NSCLC.
PARP3 has been proposed as a new, potential target to
suppress centrosome clustering, with interest in cancer
therapy [4]. At this respect, our data indicate that, at least
in some cancer cells, repression of PARP3 could be respon-
sible for an increased telomerase activity, this fact could
contribute to telomere maintenance, and avoid genome in-
stability. However, the usefulness of PARP3 inhibition in
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PARP3 could increase telomerase activity levels with a
clear relation to a proliferative advantage in cancer cells.
Conclusions
Data from this work seem to indicate that PARP3 could
acts as a negative regulator of telomerase activity. PARP3
depletion could be responsible for an increased telomer-
ase activity; this fact could contribute to telomere main-
tenance, and avoid genome instability.
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